The role of somatostatin receptor scintigraphy in the management of pituitary tumours.
The detection of functioning neuroendocrine tissue bearing somatostatin receptors has been facilitated to a large extent by the availability of radiolabelled octreotide scanning with 111In octreotide. This review discusses the possible role for somatostatin receptor scintigraphy (SRS) in the evaluation of pituitary adenomas.
Moulik
P K
PK
Department of Diabetes and Endocrinology, Royal Liverpool University Hospital, Liverpool, UK.
Varma
T R K
TR
Vora
J P
JP
Vinjamuri
S
S
D000236:Adenoma / Q000000981:diagnostic imaging* / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000378:metabolism; D006729:Hormones, Ectopic; D006801:Humans; D007205:Indium Radioisotopes; D015282:Octreotide / Q000031:analogs & derivatives; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism*; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D011986:Receptors, Somatotropin / Q000032:analysis / Q000378:metabolism*
D006729:Hormones, Ectopic; D007205:Indium Radioisotopes; D011986:Receptors, Somatotropin; D000324:Adrenocorticotropic Hormone; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D015282:Octreotide